111 / 280
BUSINESS MODEL
AND STRATEGIC
OBJECTIVES
LEADERSHIP
GOVERNANCE
OPERATING
PERFORMANCE
SHAREHOLDERS’
INFORMATION AND
ADMINISTRATION
FINANCIAL
PERFORMANCE
BLUE LABEL INTEGRATED ANNUAL REPORT 2014
109
PRESCRIBED OFFICER
DA Suntup was a prescribed officer of the Company until 14 November 2013. On that date he was appointed the
Financial Director.
DIRECTORS’ AND PRESCRIBED OFFICER’S INTERESTS
The individual interests declared by directors and officers in the Company’s share capital as at 31 May 2014, held
directly or indirectly, were as follows:
Nature of interest
Direct beneficial
Indirect beneficial
Director/officer
2014
2013
2014
2013
BM Levy
75 078 183
74 644 607
8 272 778
8 272 778
MS Levy
67 670 775
67 237 199
8 272 777
8 272 777
KM Ellerine
—
—
266 667
296 297
JS Mthimunye
30 000
30 000
—
—
MV Pamensky
—
—
5 565 738
5 565 738
LM Nestadt
—
—
8 204 674
8 204 674
GD Harlow
—
—
2 414 815
2 414 815
NN Lazarus
3 803 424
4 803 424
177 779
177 779
DB Rivkind
—
—
—
3 700 000
DA Suntup
189 037
—
3 877 778
3 877 778
SJ Vilakazi
—
—
—
—
The aggregate interest of the current directors and officers in the capital of the Company was as follows:
Number of shares
Director/officer
2014
2013
Beneficial
183 824 425
187 497 866
The beneficial interest held by directors and officers of the Company constitutes 27.69% (2013: 28.34%) of the
issued share capital of the Company.
Details of directors’ and prescribed officer emoluments and equity compensation benefits are set out in note 29 of
the Group annual financial statements and details of the forfeitable share plan are set out in note 31.
DIRECTORS’ REPORT
CONTINUED